Background: Our aim was to monitor the impact of Roux-en-Y gastric bypass (RYGBP) on body composition over a 24-month period by dual-energy X-ray absorptiometry (DXA).
Methods: Forty-one women (40.6 ± 10.0 years old; 42.6 ± 6.6 kg/m(2)) entering a bariatric surgery programme were submitted to whole-body DXA (Lunar iDXA) before treatment and after 3, 6, 12 and 24 months. Fat mass (FM), non-bone lean mass (LM), bone mineral content (BMC) and density (BMD) were measured at whole body and regionally. Android visceral adipose tissue (VAT) was estimated by a recently validated software.
Results: Twenty-nine patients (44.3 ± 11.8 years old; BMI, 45.4 ± 8.9 kg/m(2)) concluded the study. Following surgery, the progressive decrease of BMI was associated with reduced whole-body and regional FM. LM showed a moderate decrease at 3 months and stabilized thereafter. A progressive decrease of total FM/LM and android FM/LM ratios were observed in the 3- to 6-month (-19.1 ± 8.4 % and -26.5 ± 10.9 %, respectively; p < 0.0001) and 6- to 12-month periods (-23.5 ± 16.8 % and -29.4 ± 23.9 %, respectively; p < 0.0001). VAT was the parameter showing the largest decrease (-65.6 ± 17.5 % at 12 months; p < 0.0001). Two years after the surgery, a slight but significant decrease of total and regional LM was observed, without any significant change in BMI.
Conclusions: Body composition significantly changes after RYGBP with a metabolically healthier redistribution of total and regional FM and a positive balance of FM/LM variation. DXA should be considered as a valid supplementary tool for the clinical assessment and follow-up in patients undergoing bariatric surgery.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11695-014-1422-8 | DOI Listing |
Mil Med
January 2025
University of North Carolina Wilmington, Wilmington, NC 28403, USA.
Introduction: The dearth of research investigating the efficacy of virtual Army Combat Fitness Test (ACFT) training programs among female populations necessitates further exploration. This study aims to evaluate the effectiveness of a 12-week ACFT virtual exercise program among female participants.
Materials And Methods: Nine female participants (age = 19.
Health Technol Assess
January 2025
School of Medicine, Keele University, Keele, Staffordshire, UK.
Background: For people receiving haemodialysis, a balance has to be struck between removing sufficient but not too much fluid during a treatment session and maintaining any remaining kidney function they might have. In the BISTRO trial, this study sought to establish if getting the balance right might be improved by the additional use of bioimpedance, a device that measures body fluid composition to help decide how much fluid to remove during dialysis. Designing and executing this trial, which incorporated complex and repeated trial procedures that would be dependent on participant engagement, presented challenges that demanded effective public and patient involvement.
View Article and Find Full Text PDFHeliyon
January 2025
Department of Nursing, School of Health Sciences, Ariel University, Ariel, Israel.
Aims: This study evaluated the effects of circuit resistance training (CRT), a vegetarian/Mediterranean diet (VegMedD), and empagliflozin on Resting Metabolic Rate (RMR) in older adults with Type 2 Diabetes (T2DM).
Methods: 67 participants from CEV-65 trial (≥65 years, 61 % female) were randomly assigned to CRT, VegMedD, or empagliflozin for 10 weeks. Assessments included RMR, medical, metabolic, nutritional, anthropometric and functional measurements.
Brain Behav Immun Health
December 2024
Department of Psychology, University of California, Los Angeles, 502 Portola Plaza, Los Angeles, CA, 90095, USA.
Experiences of caregiving-related adversity are common and one of the strongest predictors of internalizing psychopathology (i.e., anxiety and depression).
View Article and Find Full Text PDFIndian J Endocrinol Metab
December 2024
Department of Endocrinology, Max Super Speciality Hospital, Saket, New Delhi, India.
Introduction: Oral Semaglutide (Sema-o) is the first oral glucagon like peptide-1 receptor analogue (GLP-1RA) commercially available for the treatment of type 2 diabetes (T2D). This study aimed to evaluate the efficacy of Sema-o in patients with T2D when added to the existing therapy.
Methods: This retrospective real-world study enrolled adult patients with diabetes taking Sema-o, with at least one follow-up (from February 2022 till October 2023).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!